Tvardi Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | $7.1 | $21.0 | $41.9 | $23.0 |
| Operating income | -$26.7 | -$28.1 | -$121.5 | -$87.5 | -$89.1 |
| Net income | -$18.2 | -$29.4 | -$118.5 | -$85.5 | -$88.4 |
| Cash Flow Statement | |||||
| Free cash flow | — | -$19.4 | -$94.5 | -$78.8 | -$60.1 |
Shares outstanding 13.3M
Annual filing data through FY ended December 31, 2025; float as of September 9, 2026.